Ubrogepant
Sold as Ubrelvy. Every FDA application for this active ingredient: 1 branded and 3 generic.
- First approved: Dec 23, 2019
- Applications: 4
- New uses approved: 0
- Complete response letters: 0
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 23, 2019 | UbrelvyNDA 211765 · New molecular entity | Abbvie | 4 | Marketed |
| — | UbrogepantANDA 218662 | Zydus Pharmaceuticals (USA) Inc. | 0 | Discontinued |
| — | UbrogepantANDA 219088 | Aurobindo Pharma Limited | 0 | Discontinued |
| — | UbrogepantANDA 219218 | Msn Laboratories Private Limited | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA